Clinical Trial

Testing Experimental Medication in Healthy Subjects

Study Description

A Study of the Effects of LY3372689 on the Brain in Healthy Participants

This study uses imaging to evaluate how LY3372689 binds to a protein in the brain. This study will be conducted in healthy participants and will last up to approximately 25 days after enrollment. Screening must be completed within 28 days prior to enrollment.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - LY3372689

Administered orally.

Diagnostic Test - [18F]LSN3316612

Administered IV.

Additional Information

Official Study Title

Assessment of Brain O-GlcNAcase (OGA) Enzyme Occupancy After Single Oral Doses of LY3372689 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]LSN3316612 in Healthy Subjects

Clinical Trial ID

NCT03944031

ParticipAid ID

dwpvre